Aurinia Pharmaceuticals Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases, primarily commercializing LUPKYNIS (voclosporin) for lupus nephritis and developing aritinercept. The company is incorporated in Alberta, Canada, and trades on the Nasdaq Global Market under the symbol AUPH.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $73.5 million | $67.8 million | $205.9 million | $175.3 million |
| Net Product Sales | $70.6 million | $55.5 million | $197.2 million | $158.6 million |
| Net Income | $31.6 million | $14.4 million | $76.4 million | $4.3 million |
| Diluted EPS | $0.23 | $0.10 | $0.55 | $0.03 |
| Operating Cash Flow (YTD) | $90.0 million (vs. $14.3 million YTD 2024) | |||
| Cash & Investments | $351.8 million (as of Sept 30, 2025) | |||
| Share Repurchases (YTD) | 12.2 million shares for $98.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product sales increased 27% in Q3 and 24% YTD, driven by increased market penetration of LUPKYNIS in the U.S. However, license and collaboration revenue decreased significantly (down $9.4 million in Q3) due to the absence of a $10 million one-time milestone recognized in Q3 2024 for Japanese regulatory approval.
- Profitability: The company achieved a net income of $31.6 million in Q3 2025, compared to $14.4 million in Q3 2024. Operating income improved to $29.7 million from $11.7 million.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses dropped 38% in Q3 and 46% YTD, primarily due to headcount reductions from strategic restructurings in 2024. Research and Development (R&D) expenses increased 177% in Q3 and 70% YTD, reflecting increased development activities for aritinercept.
- Restructuring: Restructuring expenses were nil in Q3 2025, compared to $7.8 million in the same period of 2024. The company noted that restructuring activities were substantially completed in the first half of 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A expenses to remain lower in 2025 as restructuring benefits are realized. R&D expenses are expected to increase as development activities continue. The company plans to initiate clinical studies with aritinercept in two autoimmune diseases by the end of 2025.
- Capital Allocation: On July 31, 2025, the Board approved an additional $150 million to the share repurchase program. As of September 30, 2025, the company had repurchased 18.3 million shares totaling $138.6 million under the program.
- Legal Proceedings:
- Patent Litigation: The company filed patent infringement lawsuits against eight generic manufacturers (including Hikma, Teva, and Sandoz) who submitted ANDAs for generic LUPKYNIS. The company asserts its 2037 patents and expects a 7.5-year exclusivity period under the Hatch-Waxman Act.
- Defamation: On November 2, 2025, the company filed a complaint for defamation and injurious falsehood against Dr. George Tidmarsh regarding false statements about voclosporin.
- Risk Factors: Potential adverse effects from U.S. government investigations into pharmaceutical imports and potential retaliatory tariffs from international governments could impact the supply chain and Otsuka's sales in international territories.
Investor Verification Checklist
- Patent Exclusivity: Verify the status of the 2037 patents and the progress of the Hatch-Waxman litigation against generic competitors.
- Restructuring Completion: Confirm that all restructuring costs have been fully recognized and that no further significant headcount reductions are planned.
- Aritinercept Pipeline: Monitor the timeline and results of the planned clinical studies for aritinercept to be initiated by the end of 2025.
- Share Repurchase Capacity: Track the remaining authorization under the expanded $300 million share repurchase program.
- Foreign Exchange Impact: Assess the impact of Swiss Franc fluctuations on the Monoplant finance lease liability, which contributed to "Other expense, net."